Silence Therapeutics, Iain Ross
Iain Ross returns to Silence Therapeutics as chairman of the board directors, nine years after he left the same role.
Ross has worked in the life sciences industry for over 40 years, in which time he has had roles at Sandoz, Roche, and at the Royal Holloway, London University. He previously performed the role of chairman for six years at Silence.
He currently holds the positions across the industry, as non-executive chairman at Redx Pharma, e-Therapeutics, and Kazia Therapeutics.
Iain Ross commented on his appointed, “I am delighted to be returning to Silence Therapeutics and I look forward to working with the new management team and all stakeholders. With a renewed strategy in place and a return to the clinic imminent, I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the board to deliver on its potential.”
Silence is working with RNA interference technology, the same area that is generating greater interest among larger companies based on Alnylam’s recent approval, and has three drug candidates that are currently at the pre-clinical stage in haematology and cardiovascular diseases.